Introduction {#s1}
============

Hearing impairment may be a modifiable risk factor for Alzheimer's disease (AD) and dementia.[@R1] However, research investigating the relationship between hearing and biomarkers of dementia-associated pathologies in preclinical populations has been limited. Improved understanding of this relationship is important to determine mechanistic relationships, and to evaluate hearing as a screening tool for dementia-associated pathologies. We investigated whether pure tone audiometry performance related to imaging biomarkers of β-amyloid deposition (Aβ), small vessel disease, grey matter macrostructure and cognitive performance in a cohort of healthy older adults all born in the same week of 1946.

Methods {#s2}
=======

We included data from 368 cognitively healthy participants drawn from Insight-46, a substudy of the MRC National Survey of Health and Development (NSHD).[@R4] All individuals were born during 1 week in 1946.

Positron emission tomography (PET) and MRI data were acquired on the same 3-Tesla PET/MRI scanner.[@R4] Aβ-burden was assessed over a 10-min period approximately 50 min after florbetapir injection (370 MBq). A standard uptake value ratio (SUVR) from a grey matter cortical composite using a white matter reference without partial volume correction was calculated. Positive or negative Aβ-status was determined using Gaussian mixture modelling (SUVR cut-point=0.6104).

MRI data included volumetric T1-weighted, T2-weighted and FLAIR images.[@R4] Cortical thickness estimation was performed using Freesurfer V.6.0.[@R5] A priori regions of interest were: primary auditory cortex (transverse temporal gyrus); planum temporale; and a surface-area weighted AD-signature composed of entorhinal, inferior temporal, middle temporal and fusiform regions.[@R6] Hippocampal volume was estimated using STEPS.[@R7] Global white matter hyperintensity volume (WMHV---a marker of small vessel disease) was estimated using BaMoS.[@R8] Total intracranial volume (TIV) was calculated using Statistical Parametric Mapping 12.

A detailed neuropsychology testing battery was performed[@R4] including: the mini-mental state examination (MMSE); digit-symbol substitution; logical memory delayed recall; matrix reasoning; and the 12-item face-name associative memory task.

An otological history regarding hearing aid use, recent ear pain/discharge, tinnitus and previous otological diagnoses was collected. Otoscopy was not performed.

Audiometric thresholds were obtained for each ear at 0.5, 1, 2, and 4 kHz using calibrated Maico-MA-25 audiometers with sound-excluding TDH-49 earphones in audiocups using a British Society of Audiology recommended testing protocol[@R9] in a quiet room. A pure-tone average (PTA) in the better hearing ear was calculated using thresholds for 0.5, 1, 2 and 4 kHz.

Wilcoxon rank sum tests were used to assess unadjusted association between binary demographic variables and PTA. Spearman correlations were used to assess unadjusted associations between continuous demographic variables and PTA.

Receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses were performed to investigate whether PTA predicted Aβ-status following adjustment for: age at scan; sex; WMHV; educational attainment[@R4]; prospective childhood cognition[@R4]; adult and childhood socioeconomic position.[@R4] Additional analyses incorporating *APOE* genotype (binarised into ε4 carrier and non-carriers) were also performed.

As WMHV was non-normally distributed, generalised linear models using the gamma distribution and log link were used to investigate whether PTA predicted WMHV.

Linear regression models with robust standard errors were used to investigate whether PTA predicted grey matter macrostructure (dependent variables=primary auditory cortex, planum temporale AD-signature thickness and hippocampal volume).

Linear regression models with robust standard errors were used to test the hypothesis that PTA predicted cognitive testing performance. For cognitive tests with skewed distributions (MMSE and Matrix Reasoning) bootstrapping with 2000 replications was used to produce bias-corrected and accelerated 95% CIs.

Analyses of WMHV, grey matter macrostructure and cognition were adjusted for age, sex, educational attainment, childhood cognitive ability, socioeconomic position, *APOE* genotype and Aβ-status. Additional adjustment for TIV was made in WMVH and hippocampal volume analyses, while analysis of grey matter macrostructure and cognition were additionally adjusted for WMHV.

Exclusions from 502 participants originally recruited included: failure to complete scan (n=31); PET acquisition failure (n=8); WMHV segmentation error (n=4); MRI movement artefact (n=3); mild cognitive impairment, dementia and/or a major neurological disorder (n=48); history of otological pathology (eg, Meniere's disease, surgery/trauma resulting in hearing loss, intercurrent infection) (n=16); equipment unavailable (n=19); missing *APOE* genotype (n=2); missing socioeconomic position (n=3).

Results {#s3}
=======

As all individuals were born in the same week, the age range at scanning was narrow (69.2--71.9 years). Median PTA across the dataset was 22.5 dB HL (decibels in hearing level) (IQR=12.5). Unadjusted associations between PTA and a range of variables are displayed in [table 1](#T1){ref-type="table"}. Of note, both tinnitus and hearing aid use were strongly associated with higher PTA ([table 1](#T1){ref-type="table"}).

###### 

Summary statistics for auditory testing/imaging biomarkers and unadjusted relationships between demographic and performance on pure tone audiometry AND associations between pure tone audiometry performance and neuropsychological testing in cognitively normal older adults

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Binary demographics                                                                            Unadjusted association with PTA                                                    
  ---------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------- -----------------------------------
  Sex                                                                                            Males: 23.5 (12.5), n=187\                   0.19\*                                
                                                                                                 Females: 21.25 (12.5), n=181                                                       

  Educational attainment                                                                         Non-advanced: 23.75 (15), n=169\             0.09\*                                
                                                                                                 Advanced: 21.25 (10), n=199                                                        

  Childhood socioeconomic position                                                               Non-manual: 22.55 (11.25), n=218\            0.95\*                                
                                                                                                 Manual: 21.25 (15), n=150                                                          

  Adulthood socioeconomic position                                                               Non-manual: 21.25 (11.25), n=313\            0.17\*                                
                                                                                                 Manual: 23.75 (16.25), n=55                                                        

  Tinnitus                                                                                       **No tinnitus: 21.25 (12.5), n=** **288**\   **0.0004\***                          
                                                                                                 **Tinnitus: 26.25 (13.75), n=** **80**                                             

  Hearing aid use                                                                                **Non-user: 21.25 (10), n=** **313**\        **\<0.0001\***                        
                                                                                                 **User: 38.75 (16.25), n=** **55**                                                 

  *APOE* genotype                                                                                Non-ε4 carrier: 22.5 (12.5), n=258\          0.089\*                               
                                                                                                 ε4 carrier: 21.25 (13.25), n=110                                                   

  Aβ positivity, n (%)                                                                           Aβ-negative: 21.88 (12.5), n=306\            0.25\*                                
                                                                                                 Aβ-positive: 23.75 (12.5), n=62                                                    

  Continuous demographics                                                                        **Summary statistic**                        **Unadjusted association with PTA**   

  Age, years, median (IQR)                                                                       70.6 (1.1), n=368                            Rho=0.07, p=0.2†                      

  Childhood cognition, z-score, median (IQR)                                                     0.48 (0.84), n=368                           Rho=−0.02, p=0.72†                    

  Cognitive tests                                                                                **Summary statistic**                        **Association with PTA**              

  **Univariate**                                                                                 **Multivariate β-coefficient‡ (95% CI**)                                           

  Logical memory delayed recall (Wechsler Memory Scale-Revised---out of 25), mean (SD)           11.6 (3.6), n=368                            r=−0.065,\                            −0.009\
                                                                                                                                              p = 0.21§                             (−0.044 to 0.026)¶

  Digit-symbol substitution (Wechsler Adult Intelligence Scale-Revised---out of 93), mean (SD)   48.8 (10.0), n=368                           r=−0.047,\                            −0.005\
                                                                                                                                              p = 0.36§                             (−0.098 to 0.087)¶

  12-item Face-Name (out of 96), mean (SD)                                                       65.6 (18.2), n=364                           r=0.099,\                             −0.01\
                                                                                                                                              p = 0.85§                             (−0.20 to 0.18)¶

  Matrix Reasoning (Wechsler Abbreviated Scale of Intelligence---out of 32), median (IQR)        25 (4), n=368                                Rho=−0.11, p=0.04§                    −0.037\
                                                                                                                                                                                    (−0.084 to 0.007)\*\*

  MMSE (out of 30), median (IQR)                                                                 30 (1), n=368                                Rho=−0.13, p=0.013§                   −**0.009**\
                                                                                                                                                                                    (**−0.019 to** **−0.001**)\*\*

  MMSE without 'No ifs, ands or buts' (out of 29), median (IQR)                                  29 (1), n=368                                Rho=−0.07, p=0.21§                    −0.005\
                                                                                                                                                                                    (−0.015 to 0.003)\*\*

   "No ifs, ands or buts" repetition (out of 1), proportion who answered Item correctly (%)      306/368, (83.2%)                             p=0.0017^a^                           −**0.031**\
                                                                                                                                                                                    (**−0.056 to** **−** **0.006**)††
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Analyses that attained statistical significance at the 5% level are highlighted in bold.

\*Wilcoxon rank sum test.

†Spearman correlation.

‡Coefficient represents increase in cognitive score per dB HL increase in PTA (covariates were: age at scan; sex; APOEε4 genotype; WMHV; educational attainment; childhood cognitive ability; socioeconomic position; and Aβ status).

§Pearson's correlation.

¶Linear regression models with robust SE.

\*\*Bootstrapping.

††Logistic regression.

Aβ, β-amyloid; AD, Alzheimer's disease; MMSE, mini-mental-state-examination; PET, positron emission tomography; PTA, pure tone average in best hearing ear; r, Pearson's r; Rho, Spearman's Rho; WMHV, white matter hyperintensity volume.

A total of 62 participants were Aβ-positive (16.8%). Unadjusted analyses revealed no evidence of an association between Aβ and PTA ([table 1](#T1){ref-type="table"}). Using a base model combining age, sex, WMHV, educational attainment, childhood cognitive ability and socioeconomic position, ROC analysis provided an AUC for Aβ-positivity of 0.55 (95% CI 0.48 to 0.63); subsequent inclusion of PTA (AUC=0.56, 95% CI 0.49 to 0.64) did not improve the predictive ability. Incorporating *APOE* genotype into the base model provided an AUC for Aβ-positivity of 0.70 (95% CI 0.62 to 0.78). Again, inclusion of PTA (AUC=0.72; 95% CI 0.64 to 0.79) did not improve this.

There was no evidence that PTA predicted WMHV in fully adjusted models (exponentiated coefficient=0.96; 95% CI 0.98 to 1.01; p=0.39, which corresponds to the proportional change in WMHV per dB HL increase in PTA).

There was evidence of a negative association between primary auditory cortex thickness and PTA ([figure 1](#F1){ref-type="fig"}). No associations were observed between PTA and planum temporale thickness, AD-signature thickness or hippocampal volume ([figure 1](#F1){ref-type="fig"}).

![Association between pure tone audiometry performance and grey matter structural metrics in cognitively normal older adults following multivariate linear regression with robust SE. Covariates included: age at scan; sex,; *APOE*ε4 genotype; WMHV; educational attainment; childhood cognitive ability; socioeconomic position'Aβ status; and TIV (for hippocampal volume analysis only). Solid line represents line of best of fit. Dashed lines represent 95% CIs. The crosses represent raw unadjusted data points for each individual included in the analysis. AD, Alzheimer's disease; PTA, pure tone average in best hearing ear; TIV, total intracranial volume; WMHV, white matter hyperintensity volume.](jnnp-2019-321897f01){#F1}

There was no evidence of a relationship between PTA and a range of cognitive scores following covariate adjustment, except for a negative association between PTA and MMSE. However, this was no longer evident when excluding the phrase repetition item 'no ifs, ands, or buts' ([table 1](#T1){ref-type="table"}).

A post-hoc analysis using high frequency thresholds only (4 kHz rather than a PTA) was performed and produced very similar results (data not shown).

Discussion {#s4}
==========

We found no evidence of an association between PTA and Aβ-deposition in cognitively healthy individuals aged 69.2--71.9 years. To our knowledge, this is the first study to investigate the relationship between hearing and PET-derived measures of Aβ, although a null relationship between cerebrospinal fluid biomarkers of Aβ-deposition and auditory function has been reported in healthy older adults with a family history of AD.[@R10] There was also no evidence of a relationship between PTA and WMHV, which to our knowledge has not been investigated previously. Taken together these results suggest impaired hearing is not a reliable marker of preclinical Aβ-deposition or small vessel disease, at least early in the eighth decade. This is supported by a recent systematic review and meta-analysis, which found evidence that hearing impairment increased the risk of cognitive impairment and all-cause dementia, but did not increase the risk for AD or vascular dementia specifically.[@R11]

Beyond Aβ and small vessel disease, another potential pathophysiological mechanism linking hearing and dementia is neurodegeneration. Hearing loss has been previously shown to be associated with grey matter atrophy including regions typically affected in AD.[@R10] However, in our analyses, neither hippocampal volume nor AD-cortical signature thickness were associated with PTA, suggesting that hearing impairment is unlikely to be related to AD-pattern neurodegeneration in healthy older adults. In contrast we found evidence for an independent association between PTA and primary auditory cortex thickness, which has been shown previously,[@R13] but not with consideration of Aβ and WMHV. Although speculative, this would be consistent either with a non-AD and non-vascular related degeneration of this region contributing to hearing impairment, or with peripheral deafferentation of the cochlear nerve due to presbycusis leading to atrophy in primary auditory areas, although the cross-sectional nature of the data limits ability to infer a causal direction. Furthermore, the association observed was cross-sectional and relatively weak statistically following adjustment for covariates necessitating cautious interpretation.

In terms of cognition, the only significant finding was an association between PTA and MMSE score, which was no longer evident when a test item assessing repetition of a single phrase ('no ifs, ands or buts') was excluded, suggesting that although hearing ability had limited impact on overall cognitive function, hearing loss may impact acoustically demanding tests and is an important consideration while administering and interpreting such tests.

Limitations include: its cross-sectional nature; missing data; lack of a more detailed otological examination; and inability to precisely define causes of hearing loss. Future work of importance will include inclusion of longitudinal auditory, cognitive and neuroimaging data, and long-term follow-up. It is possible that auditory dysfunction *does* precede the development of cognitive impairment in AD, but that this occurs sometime after Aβ-deposition; individuals in this study are aged 69.2--71.9 years and may be many years away from developing cognitive impairment, and the downstream pathological changes associated with hearing impairment. Neuroimaging techniques that assess other pathological process relevant to dementia such as tau-PET,[@R14] may provide further insights. Including a broader range of auditory testing, specifically including tests that focus on central auditory processing,[@R15] which is known to be impaired in established AD will also be of considerable interest. The majority of participants investigated had normal hearing thresholds, which may limit the power to detect relationships between hearing function and outcomes relevant to dementia. However, the statistically significant relationships observed between tinnitus, hearing aid use and primary auditory cortex thickness would support the notion that this study is sufficiently powered to detect meaningful relationships between hearing function and outcomes of interest.

In summary, we demonstrate that pure tone audiometry performance did not predict concurrent Aβ-deposition, small vessel disease or AD-pattern neurodegeneration, and had limited impact on cognitive function, in healthy adults aged approximately 70 years.
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